Bioengineering & Translational Medicine (Jan 2024)

Distinguished biomimetic dECM system facilitates early detection of metastatic breast cancer cells

  • Bowen Weng,
  • Mei Li,
  • Weilai Zhu,
  • Jing Peng,
  • Xufeng Mao,
  • Yanan Zheng,
  • Chi Zhang,
  • Senhao Pan,
  • Haijiao Mao,
  • Jiyuan Zhao

DOI
https://doi.org/10.1002/btm2.10597
Journal volume & issue
Vol. 9, no. 1
pp. n/a – n/a

Abstract

Read online

Abstract Breast cancer is the most prevalent malignant tumor affecting women's health. Bone is the most common distant metastatic organ, worsening the quality of life and increasing the mortality of patients. Early detection of breast cancer bone metastasis is urgent for halting disease progression and improving tumor prognosis. Recently, extracellular matrix (ECM) with biomimetic tissue niches opened a new avenue for tumor models in vitro. Here, we developed a biomimetic decellularized ECM (dECM) system to recapitulate bone niches at different situations, bone mimetic dECM from osteoblasts (BM‐ECM) and bone tumor mimetic dECM from osteosarcoma cells (OS‐ECM). The two kinds of dECMs exhibited distinct morphology, protein composition, and distribution. Interestingly, highly metastatic breast cancer cells tended to adhere and migrate on BM‐ECM, while lowly metastatic breast cancer cells preferred the OS‐ECM niche. Epithelial‐to‐mesenchymal transition was a potential mechanism to initiate the breast cancer cell migration on different biomimetic dECMs. Importantly, in the nude mice model, the dECM system captured metastatic breast cancer cells as early as 10 days after orthotopic transplantation in mammary gland pads, with higher signal on BM‐ECM than that on OS‐ECM. Collectively, the biomimetic dECM system might be a promising tumor model to distinguish the metastatic ability of breast cancer cells in vitro and to facilitate early detection of metastatic breast cancer cells in vivo, contributing to the diagnosis of breast cancer bone metastasis.

Keywords